Fig. 3
From: Apolipoprotein A-IV binds αIIbβ3 integrin and inhibits thrombosis
ApoA-IV inhibits platelet aggregation in vitro. a Enhanced platelet aggregation in platelet-rich plasma (PRP) from apoA-IV−/− mice (n = 5, P < 0.05) induced by ADP (1 μM), collagen (1 μg/mL) and TRAP (250 μM). b Enhanced apoA-IV−/− and apoA-IV+/+ platelet aggregation in apoA-IV−/− plasma (n = 3, P < 0.05). ApoA-IV−/− and apoA-IV+/+ platelet-poor plasma (PPP) were prepared and incubated with either ApoA-IV−/− or apoA-IV+/+ gel-filtered platelets. Platelet aggregation was induced by TRAP (250 μM). c No significant difference in aggregation between gel-filtered apoA-IV+/+ and apoA-IV−/− platelets in PIPES buffer induced by TRAP (250 μM) (n = 3). d Dose-dependent inhibition of ADP (1 μM) -induced platelet aggregation in mouse PRP by recombinant mouse apoA-IV. Areas under the curves for each group were compared to control (n = 4, P < 0.05). e Dose-dependent inhibition of ADP (2.5 μM) -induced platelet aggregation in human PRP by recombinant human apoA-IV (n = 4, P < 0.05). f Depletion of human plasma apoA-IV from healthy donors with different ethnic backgrounds, by a goat anti-human apoA-IV IgG, enhanced ADP-induced platelet aggregation (n = 4). Non-specific goat IgG treated plasma was used as control. ApoA-IV-depleted PPP was shown by western blot (Supplementary Fig. 17). g Transgenic mice overexpressing mouse apoA-IV had markedly attenuated platelet aggregation induced by ADP (1 μM) (n = 4). Aggregation traces are representative of several independent experiments indicated. The maximum platelet aggregation in each group was compared to control unless otherwise indicated. PPP platelet poor plasma, rM-apoA-IV recombinant mouse apoA-IV, rH-apoA-IV recombinant human apoA-IV, ApoA-IV-Tg transgenic mice overexpressing mouse apoA-IV. Unpaired, two-tailed Student’s t-test or non-parametric Kruskal-Wallis one-way analysis of variance for multiple paired comparisons. Mean ± SEM. **P < 0.01. Scale bars: 2 minute (a–g)
